Vitrafy Life Sciences (VFY) investor relations material

Executive summary

• Q1 FY27 expanded U.S. civilian blood partnerships and entered the cell and gene therapy market through Charter Medical, alongside progress toward FDA medical device listing.

• Cash and term deposits totaled A$38.3m at 30 September 2026, supporting validation, manufacturing scale-up and market development.

Financial highlights

• Net operating cash outflow was A$4.857m; customer receipts were A$113k, grants A$328k and interest received A$364k.

• Quarterly cash expenditure was A$5.7m, versus A$5.6m in the prior quarter; average monthly cash burn was ~A$1.9m.

• Cash and cash equivalents were A$23.174m, with A$15m in term deposits and a restricted A$75k deposit at quarter-end.

• Current funding supports operations into calendar 2028; higher device demand could require additional funding flexibility.

Outlook and guidance

• Guardion FDA medical device listing remains targeted by end of 1H FY27; verification is progressing and plasma validation studies are being prepared with USAISR.

• H1 FY27 priorities include FDA listing, establishing a U.S. headquarters with CEO relocation, and converting blood and CGT pipeline opportunities.

• First medical device fleet production is planned for H2 FY27; U.S. manufacturing is targeted to be on stream in 2H 2027.

• Cash costs are expected to rise as validation, U.S. hiring, manufacturing capacity and initial fleet investment ramp up.

• Management aims to increase U.S. blood-network market capture from ~17% to above 50% over the next 6–12 months.